A clinician opens an AI assistant and types a question about a therapy. The model returns one fluent paragraph that names a drug, summarizes its benefit, and may or may not mention a risk. That paragraph behaves like promotion. It characterizes a prescription product to a prescriber, and it shapes a decision. But inside the manufacturer, no single function owns it. Brand owns the website and the campaign. Medical owns the evidence and the scientific narrative. Regulatory owns the MLR process and the label. The AI answer falls into the gap between all three, and gaps do not review themselves.
This is not a tooling problem first. It is an ownership problem. Before any dashboard helps, someone inside the company has to be accountable for what AI says about the brand, on a standing basis, against a standard. This article is about that operating model: the standard the answer is held to, why a working group is not enough, the single spine that lets every function share one ground truth, and a practical cadence for who does what when an answer goes wrong.
The answer carries a regulatory standard, even though you did not write it
The instinct is to treat an AI answer as someone else's output. The model wrote it, the argument goes, so it is the model's problem. That instinct does not survive contact with the standard.
US regulation sets a clear bar for how a prescription drug may be characterized. Under 21 CFR 202.1(e)(5), promotional communication does not present a true statement if it is "false or misleading," if it "fails to present a fair balance" between risk and effectiveness, or if it "fails to reveal facts material in the light of its representations" (Legal Information Institute, 21 CFR 202.1). The Office of Prescription Drug Promotion frames its mission as assuring that prescription drug information is "truthful, balanced and accurately communicated." The standard attaches to the communication and to the characterization of the drug, not to the identity of whoever happened to author the sentence.
Read that against an AI answer that lists a therapy's efficacy and omits its contraindication. If a brand team had published that sentence in a sales aid, it would fail fair balance on its face. The clinician reading it on screen cannot tell whether a copywriter, a search index, or a language model produced it. The characterization is the same, the audience is the same, and the consequence of acting on it is the same. The reach of the regulation is the regulated promotional context, not literally every sentence ever generated, so this is an argument about exposure and duty of care rather than a settled enforcement theory. But the direction is not subtle: a company that monitors, corrects, and documents what AI says about its brand is in a defensible posture, and a company that treats the answer as nobody's job is not.
And this is not a fringe channel. The AMA's 2026 physician survey found that awareness or use of AI in practice rose to 81% in 2026, up from 66% in 2024, with the share reporting no AI use falling from 34% to 19% (AMA 2026 Physician Survey on Augmented Intelligence). Doximity's 2026 report put physicians currently using AI in clinical practice at 54%, with literature search the most common use case (Doximity 2026 State of AI in Medicine Report). The behavior is mainstream. The governance is not yet.
A working group is not an operating model
The common first response is to stand up a cross-functional working group: Brand, Medical, and Regulatory meet monthly, look at some AI outputs, and agree to keep an eye on it. That is a useful start and an inadequate end.
A working group is episodic. The thing it is meant to govern is continuous. AI answers change as models are retrained, as the web they read shifts, and as competitors publish. The same question can return a different brand, a different framing, and a different set of citations on a different engine or a different day. A monthly meeting reviewing last month's screenshots is reviewing a surface that has already moved. Worse, a working group with shared awareness but no named accountability produces the exact failure it was convened to prevent: everyone has seen the problem and no one owns the fix.
An operating model is the upgrade. It has a standing input (what the AI is saying, measured continuously), a standard (the approved label and the rules derived from it), named owners for each kind of problem, a defined cadence, and an audit trail. The difference between a working group and an operating model is the difference between noticing and operating.
The spine is the approved label, not the org chart
The reason ownership fragments is that each function reasons from a different artifact. Brand reasons from the campaign brief, Medical from the evidence dossier, Regulatory from the label and the MLR record. When an AI answer is wrong, three functions look at three different sources of truth and reach three different conclusions about whether it even is wrong.
The fix is to give every function the same ground truth, and the only artifact that already carries the authority to be that ground truth is the approved label. The label defines the approved indication, the population, the dosing, the safety information, and the boundary of every on-label claim. It is the thing Regulatory already owns and the thing MLR already enforces. Make it the spine, and a question that used to be a matter of opinion ("is this answer acceptable?") becomes a matter of comparison ("does this answer match the label?").
This is the core architectural move, and it is where the inside and the outside of the company finally join. The same approved label drives two activities that have historically lived in separate buildings. Inside, before a marketing asset goes to MLR, a pre-check compares the asset's claims against the label so the preventable, mechanical failures are caught before a human reviewer ever opens the file. Outside, answer monitoring compares what AI engines say about the brand against the same label, so an off-label characterization or a broken fair balance is flagged as an incident. One label, two checks, one ground truth. The asset your team wrote and the answer the model wrote are graded against the identical standard. That join is what makes Claim Uptake measurable against what you actually approved rather than guessed, and it is what makes a Risk of Answer flag defensible rather than subjective.
The operating cadence: a RACI on one label
With the label as the spine, the operating model becomes specific. Juncture's Answer Monitor reports six Core KPIs (Share of Answer, Ecosystem Share of Answer, Precision of Answer, Risk of Answer, Claim Uptake, and Top References), defined in detail on the answer monitor page. The point here is not to redefine them. The point is to assign them. Each KPI movement maps to a different owner and a different response, and writing that mapping down is most of the work.
The label baseline is owned by Regulatory. Regulatory maintains the current approved label inside the platform as the versioned source of truth that both the pre-check and the monitor read. When the label changes, the baseline changes once, in one place, and both the inside and outside checks inherit it. This is the single most important ownership line, because if the spine drifts, everything downstream drifts with it. Regulatory is Accountable; Medical is Consulted on the clinical content.
A Risk of Answer spike is reviewed by Medical and Regulatory, together, as an incident. Risk of Answer is the one KPI where a rising number is bad: it counts answers that state an unapproved use as fact, overstate a benefit, omit a material risk, or break fair balance. A spike is not a metric to note in a slide. It is an event with a clock. Medical assesses the clinical accuracy of the offending answer, Regulatory assesses the promotional and labeling exposure, and the two decide jointly on the response: correct the underlying source, strengthen the approved content the models should be reading, or escalate. Brand is Informed, not deciding, because this is a compliance event, not a marketing one.
Claim Uptake is owned by Brand and Medical. Claim Uptake measures how many of your approved, on-label claims actually appear in AI answers. Low uptake means the models are filling the vacuum with third-party sources because your approved language is not present or not legible to them. That is a content and evidence problem, which is Brand's and Medical's to fix by producing and surfacing better approved content, drawn from the content intelligence library so the claims are reused verbatim rather than re-litigated. Regulatory is Consulted to confirm the claims remain on-label.
Share of Answer, Ecosystem Share of Answer, and Top References sit with Brand, read for competitive position and for which sources the engines actually cite, with Medical Consulted on whether a high-influence citation is scientifically sound. Precision of Answer, accuracy of the mention against the label, is a shared read between Medical and Regulatory.
Underneath all of it runs the audit trail, and the audit trail is what makes the model defensible rather than merely diligent. Every monitored answer, the KPI it moved, the owner who reviewed it, the decision they made, and the label version it was judged against should be captured in a time-stamped, non-editable record. If a regulator or an internal auditor later asks what the company knew about how AI was characterizing its brand and what it did about it, the answer is a log, not a recollection. This mirrors the discipline already expected of the inside review: the same Part 11-supporting trail that backs an MLR sign-off should back an answer-monitoring decision.
A worked example: Varigel
Take a fictional therapy, Varigel, approved for one narrow indication with a contraindication for patients on a common comorbidity medication. The weekly monitor run surfaces three things. Share of Answer is healthy at 40-odd percent, so Brand is not alarmed on visibility. But Risk of Answer ticks up: two answers this week describe Varigel for a broader population than the label allows, and one omits the contraindication. That is an incident. Medical and Regulatory open it the same day, compare both answers against the label version on record, confirm the off-label characterization, and trace it to an outdated third-party guideline the engines are leaning on (visible in Top References). The fix is twofold: Brand and Medical publish stronger approved content covering the correct population and surface the contraindication prominently, and the team logs the whole sequence. Meanwhile Claim Uptake shows only two of nine approved claims appearing regularly, which becomes Brand and Medical's standing work item, not a fire. None of this required a new meeting to be invented. It required the meeting that already exists to have a named owner, a label to point at, and a record to leave behind.
Where Juncture fits
The answer your customer reads from an AI assistant is a communication about your drug, held to the same standard as anything your team writes, whether or not your team wrote it. Owning it does not mean controlling the model. It means running an operating model: one approved label as the spine, named owners for each KPI, a cadence that matches the continuous nature of the problem, and an audit trail that makes the whole thing defensible.
Juncture is the instrument for that model. Pre-check clears your assets against the label before MLR, Content Intelligence holds the approved, modular claims library that feeds both your content and the models, and Answer Monitor measures what AI says against the same label on the outside. One label drives all three, so the inside and the outside finally share a ground truth. See the platform for how the pieces join, and read the companion piece on where HCPs actually use AI to understand the surfaces this model has to govern.